MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers. - sprookjes - yvandenbroek - TriplyDB

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers.

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers.

http://www.wikidata.org/entity/Q34258717

about

Role of Endoscopy in Diagnosis and Management of Pediatric Eosinophilic Esophagitis Allergic mechanisms of Eosinophilic oesophagitis Recent advances in understanding/managing eosinophilic esophagitis in adults The pathophysiology of eosinophilic esophagitis A Gene Expression Panel is Accurate for Diagnosis and Monitoring Treatment of Eosinophilic Esophagitis in Adults.Genetic and epigenetic underpinnings of eosinophilic esophagitis Specific MicroRNA Pattern in Colon Tissue of Young Children with Eosinophilic Colitis.Management of refractory eosinophilic esophagitis.Computational prediction of disease microRNAs in domestic animals Non- and semi-invasive methods of monitoring eosinophilic esophagitis.Increased prevalence of eosinophilic gastrointestinal disorders in pediatric PTEN hamartoma tumor syndromes Analysis and expansion of the eosinophilic esophagitis transcriptome by RNA sequencing MicroRNA profiling in mucosal biopsies of eosinophilic esophagitis patients pre and post treatment with steroids and relationship with mRNA targets Pediatric eosinophilic esophagitis is associated with changes in esophageal microRNAs.Decreased expression of microRNA-21 correlates with the imbalance of Th17 and Treg cells in patients with rheumatoid arthritis.Targeted ablation of miR-21 decreases murine eosinophil progenitor cell growth.miRNAs can be generally associated with human pathologies as exemplified for miR-144.Systems biology of asthma and allergic diseases: a multiscale approach Predictors of response to steroid therapy for eosinophilic esophagitis and treatment of steroid-refractory patients Changes of micro-RNAs in asymptomatic subjects sensitized to Japanese cedar pollen after prophylactic sublingual immunotherapy.Molecular, genetic, and cellular bases for treating eosinophilic esophagitis.MiR-3162-3p Is a Novel MicroRNA That Exacerbates Asthma by Regulating β-Catenin.Utility of a Noninvasive Serum Biomarker Panel for Diagnosis and Monitoring of Eosinophilic Esophagitis: A Prospective Study.Confounding factors affect the pathophysiology of eosinophilic esophagitis ATG7 Gene Expression as a Novel Tissue Biomarker in Eosinophilic Esophagitis MiR-223 deficiency increases eosinophil progenitor proliferation The Impact of Hemolysis on Cell-Free microRNA Biomarkers.The Immunologic Mechanisms of Eosinophilic Esophagitis.Differential microRNA epression in asthma and the role of miR-1248 in regulation of IL-5.Mechanisms of Disease of Eosinophilic Esophagitis.Diagnostic, functional, and therapeutic roles of microRNA in allergic diseases.miR-675-5p enhances tumorigenesis and metastasis of esophageal squamous cell carcinoma by targeting REPS2.MicroRNAs act complementarily to regulate disease-related mRNA modules in human diseases.Possible Noninvasive Biomarker of Eosinophilic Esophagitis: Clinical and Experimental Evidence.Correlation of increased PARP14 and CCL26 expression in biopsies from children with eosinophilic esophagitis.Emerging drugs for eosinophilic esophagitis.Cellular and molecular immunological mechanisms in eosinophilic esophagitis: an updated overview of their clinical implications.MicroRNA regulation of allergic inflammation and asthma.MicroRNAs in Allergic Disease.microRNA and Allergy.

P2860

Q26776253-D8E711ED-2553-40FB-BC59-4082D8B2D1FF Q26778315-5504F2C9-2448-4CD0-821D-3DD682E27267 Q26784606-AE66BFE7-7FA3-4B10-9876-CD11F711D6A2 Q27011378-6E89D961-9724-4B0C-953F-7F308876D9B9 Q30844945-C0364425-4993-499A-9BF4-8071760F771D Q33606257-CB10ABEB-216F-4672-9764-2F65F3001E26 Q33755299-C8505297-FC95-46A9-B7A6-A2CB102CCF04 Q33844314-508AA444-B017-4E57-B779-F4B75F55CD45 Q33881021-A99219F0-A4C1-4C89-AC41-240D02254AAD Q34026678-44FBA14A-C842-4D2C-A0F7-D3F10E0A491A Q34030947-FE1205EB-4FFD-412D-961F-CBE58A67AF9B Q34143183-AEC94DEE-DDDC-43DD-9BB7-C982D3C1348F Q34345019-8C65FDCE-396A-4216-B3CE-1F2022B6AC08 Q34356060-6C72863D-9B3F-4E71-8658-4C0ACE579BDB Q34473650-44FB519E-536F-478B-8341-878875BBF227 Q34637817-3F35B2FF-1BEF-4EF0-AA9A-4490EC948939 Q34720619-E00D0001-88AF-466F-8710-4327A34F40FA Q34892932-0E082EC4-FD2A-425B-BCB2-CA7ADD19C47E Q35032854-2214CA4A-B0FF-48B5-9839-2412FE59E21B Q35306850-0F6A3913-54B5-4C7E-9EF3-9E472203282B Q35537424-F59D270D-E156-4832-9B21-A1AE733EF0E9 Q35951046-9B7D63B1-3A9D-48F0-96EF-B02DFEA63664 Q36082838-E1EBAA13-0EF1-4274-B1CD-0D004EFF5F3A Q36214525-4A9A8F77-9EB2-4765-83A4-42C8072E579C Q36496752-C27A52CA-307E-4A65-805B-F34F942FF9E2 Q36586129-BAEB80B0-C7E1-4B29-9E24-1AB8CFF21D1B Q36872732-C3D993C1-B265-4F8E-AEA6-2F7E614FFF27 Q37019844-2C5AA010-5EF7-41DB-BFB5-3E0AE4017C2B Q37021673-645D080A-474C-438A-A977-0B1EFD85FB5B Q37031313-059D665F-2A7C-48DD-A6C0-0DE7024A640E Q37080521-0CB7BEF5-31F4-4178-ADB8-C079B13E15CC Q37327593-B7F92598-6E97-4920-8BCA-72D9E6AAABBE Q37365343-D3126818-F347-49ED-AAF5-6E8303C255E2 Q37449004-B3FBFE3A-6F63-4A5A-B958-5CB25A3879AF Q37649772-9D74698A-B0C9-43F1-A69E-0D128F5870EB Q38128368-37E18E2D-AF30-4E41-9CE5-D764DD4BAE68 Q38205271-52D747D8-37DC-4135-BB93-6C2A8E86EC02 Q38562722-BCFAC7E3-2C15-43DA-A663-72B4DB62F0BB Q38825287-E7329366-F26B-41AE-B661-D8175FEA9AD9 Q38932407-988D810A-3A8F-4DBC-8379-F9E828C178AE

P2860

MicroRNA signature in patients with eosinophilic esophagitis, reversibility with glucocorticoids, and assessment as disease biomarkers.

http://www.wikidata.org/entity/Q34258717

description

2012 nî lūn-bûn

@nan

2012 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի մարտին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

MicroRNA signature in patients ...... essment as disease biomarkers.

@ast

MicroRNA signature in patients ...... essment as disease biomarkers.

@en

MicroRNA signature in patients ...... essment as disease biomarkers.

@nl

type

label

MicroRNA signature in patients ...... essment as disease biomarkers.

@ast

MicroRNA signature in patients ...... essment as disease biomarkers.

@en

MicroRNA signature in patients ...... essment as disease biomarkers.

@nl

prefLabel

MicroRNA signature in patients ...... essment as disease biomarkers.

@ast

MicroRNA signature in patients ...... essment as disease biomarkers.

@en

MicroRNA signature in patients ...... essment as disease biomarkers.

@nl

P1433

Q34258717-EDA1CC67-D0A4-484C-BFD3-0A26669B8DB0

P1476

Q34258717-D7F92065-FC3F-43A6-B3D2-47F4266DCD21

P2093

Q34258717-01246216-66A2-4B95-A898-B30915DF9DAD

Q34258717-0A51EB4F-41E9-4639-9DD1-2BBA520F8AC3

Q34258717-0C6BAB6A-814B-47E0-9C86-3A5748D515A5

Q34258717-78789C07-F273-4B16-A4AD-EC1A8BC7D715

Q34258717-9C23E9F8-2DFD-4572-B5E5-64EC89CF54C4

Q34258717-B3E2B695-3284-4320-80B2-D2A7E745BC64

Q34258717-E60B18E5-4433-4BB4-874A-45767B800FF7

Q34258717-F3BC94C4-CB94-4737-BED3-E2B13B5E758B

P2860

Q34258717-04A2766D-A55D-4B83-B287-B85B7CB2E6BC

Q34258717-0BCDEB35-8D9C-44A7-8597-DEFD21A12599

Q34258717-11EE9707-55E6-4DAF-9914-120A3CF516AE

Q34258717-1355D989-090C-490F-8EE2-B574290F77C6

Q34258717-1719CEC2-8313-4EF9-9D42-DB7B9E568B67

Q34258717-19EEAF89-0BCB-4571-9C07-228DC74AE973

Q34258717-222CAEC3-1CDB-4196-9824-56D9D09A9F03

Q34258717-2409FF09-317E-4894-82AE-E572E393B2E8

Q34258717-2AF7EABA-E166-4E1A-BF2C-A803996B79AA

Q34258717-37E52FE6-BD8E-4329-A16E-F59F431E92C4

P304

Q34258717-D394355C-6DC6-4EE7-84DA-DE1E91DC80B0

P31

Q34258717-0A50E3AE-FFDB-4168-BC4C-E54ED89AC667

P356

Q34258717-8FA54392-F98A-4927-B936-27FCAAA40620

P407

Q34258717-651536E3-A52A-4242-872E-4137A670BEF6

P433

Q34258717-F28DD974-0FB0-4E28-91CA-5DD79F4475E2

P478

Q34258717-5E5B4060-1B2D-423E-A787-FE22E63F3589

P50

Q34258717-164ABD90-32EF-467D-BA50-16BC73C4F52D

Q34258717-ADF6E504-E70E-46B4-AD33-CB3686C304F1

Q34258717-B17663C5-AA1E-4F97-A8A1-BC3DC67C0C1C

Q34258717-F5683E57-08C2-481E-B6D8-CCDC3975175F

P577

Q34258717-DB80B330-D5D3-4BA8-83E3-4EE8C132FBB9

P5875

Q34258717-8A60EDB2-60A9-4635-A180-7AFFBCF94286

P698

Q34258717-17C06F8C-5ACC-4119-BDB3-AA00D02F076D

P921

Q34258717-201ACFB2-E806-4701-A264-3B772CF4B48C

Q34258717-671FCA72-891D-4562-8EDC-34B83186A1AD

Q34258717-813D6D6F-575B-4626-A936-34A75D3D01EA

P932

Q34258717-5DC617E2-346E-4053-AE1E-0DF19FC924EE

P356

J.JACI.2012.01.060

P1433

The Journal of Allergy and Clinical Immunology

P1476

MicroRNA signature in patients ...... essment as disease biomarkers.

@en

P2093

Andrew J Plassard

http://www.w3.org/2001/XMLSchema#string

James P Franciosi

http://www.w3.org/2001/XMLSchema#string

John A Besse

http://www.w3.org/2001/XMLSchema#string

Joseph D Sherrill

http://www.w3.org/2001/XMLSchema#string

Marc E Rothenberg

http://www.w3.org/2001/XMLSchema#string

Michael Eby

http://www.w3.org/2001/XMLSchema#string

Philip E Putnam

http://www.w3.org/2001/XMLSchema#string

Ting Wen

http://www.w3.org/2001/XMLSchema#string

P2860

MicroRNAs: novel regulators involved in the pathogenesis of psoriasis?

Proinflammatory role for let-7 microRNAS in experimental asthma

MicroRNA-210 regulates cancer cell proliferation through targeting fibroblast growth factor receptor-like 1 (FGFRL1)

Antagonism of microRNA-126 suppresses the effector function of TH2 cells and the development of allergic airways disease

miRBase: tools for microRNA genomics

Circulating microRNAs as stable blood-based markers for cancer detection.

MicroRNA-221-222 regulate the cell cycle in mast cells

Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells

Let-7 microRNA-mediated regulation of IL-13 and allergic airway inflammation

Argonaute2 complexes carry a population of circulating microRNAs independent of vesicles in human plasma

P304

1064-75.e9

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JACI.2012.01.060

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Juan Pablo Abonia

P577

2012-03-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

221888770

http://www.w3.org/2001/XMLSchema#string

P698

22391115

http://www.w3.org/2001/XMLSchema#string

P921

P932

3466056

http://www.w3.org/2001/XMLSchema#string